Skip to main content
. 2022 Oct 18;113(1):124–134. doi: 10.1002/cpt.2743

Figure 2.

Figure 2

Univariate impact of covariates on relugolix AUCss upon the recommended dosing regimen (a 360‐mg loading dose, followed by a 120‐mg daily dose). Numbers represent percentage change from the AUCss value in a reference man in the phase III study population: non‐Black/African American race, median body weight (80 kg), and median age (72 years). Bars represent the relative change (%) from the reference value. AUCss, area under the relugolix concentration‐time curve over a dosing interval at steady‐state.